Anti-bit

Quick links to important sections

Anti-bit

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anti-bit

Property Description
Active Ingredient Phenothrin (d-Phenothrin)
Form Topical (Shampoo, Solution, Lotion, Spray)
Pharmacological Class Ectoparasiticide, Synthetic Pyrethroid
General Purpose Elimination of surface parasitic infestations
Origin Synthetic (Pyrethroid Ester)

Anti-bit is a medicinal preparation classified as an ectoparasiticide, meaning its purpose is to eliminate parasites that live on the outer surface of the body, most commonly used against lice infestations in humans. The core active substance in this preparation is Phenothrin, also widely known by the synonym Sumithrin. This compound is categorized as a synthetic pyrethroid insecticide. Phenothrin is an engineered pyrethroid ester, distinguishing it as a man-made substance from older, naturally derived pyrethrins. This class of compounds is utilized for its action against common ectoparasites.


What Type of Ectoparasiticide is Anti-bit?

Anti-bit is a single active ingredient product containing only Phenothrin. The active substance is classified under the Anatomical Therapeutic Chemical (ATC) code P03AC03, which encompasses pyrethrins and synthetic compounds used against ectoparasites. Phenothrin acts specifically by modulating sodium channels in the nervous system of the target pests, leading to rapid paralysis. This confirms that the medicine works by quickly disrupting the parasite's nerve signals to halt movement.

The drug entity is available exclusively in topical dosage forms, which include a shampoo, solution, lotion, and sometimes an aerosol spray. These preparations utilize specialized topical bases, such as hydroalcoholic or surfactant-based systems, designed to ensure the effective, non-systemic delivery of Phenothrin directly to the hair and skin where the parasitic infestation resides. Anti-bit preparations are typically positioned for treating head lice in children and adults, providing an established use scenario for this formulation.


What is the General Purpose of Phenothrin?

The general purpose of Phenothrin is to eliminate surface parasitic infestations through its action as a neurotoxic agent targeting the pests. By rapidly immobilizing and eliminating the ectoparasites, Anti-bit serves the fundamental purpose of breaking the infestation cycle and providing quick relief from the physical symptoms caused by the presence of these parasites.

Regulatory References

  1. Voltage-gated sodium channels as targets for pyrethroid insecticides

What side effects are possible with Anti-bit?

Possible Side Effects and Safety Information

The safety profile of this topical preparation, containing Phenothrin, is primarily defined by local application-site reactions and regulatory statements on systemic risk. The majority of reported effects are temporary and limited to the area of contact. Standardized frequency classifications (e.g., 'Common,' 'Rare') are not consistently documented across all regulatory summaries for this specific topical use.

Adverse Reaction Categories and Systems

Adverse reactions are primarily associated with the following System-Organ Classes as documented in official safety literature:

  • Skin and Subcutaneous Tissue Disorders: The most frequently reported effect is tingling or numbness (paresthesia), along with itching (pruritus), localized redness (erythema), or rash [1.1], [3.3]. These sensations typically begin within one to two hours of application and usually resolve within 48 hours.
  • Eye Disorders: Reactions include eye irritation, burning, and excessive tearing (lacrimation) following contact [1.1].
  • Respiratory Disorders: Exposure via inhalation can cause mild respiratory tract irritation, coughing, or shortness of breath [1.1].

Serious Adverse Reactions and Safety Constraints

Serious systemic reactions, such as convulsions or coma, are documented in official safety reports but are associated with substantial exposure or accidental ingestion rather than typical topical use [3.1], [3.6].

Regulatory assessments include specific safety constraints for vulnerable groups. Official documents note the potential for increased susceptibility in children and infants when compared to adults, a factor addressed in risk assessments [2.5], [2.1]. Furthermore, safety evaluations have classified the active ingredient as not likely to be a human carcinogen by all routes of exposure [3.3]. Repeated or prolonged contact may lead to the persistence of localized skin reactions [1.1].

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope and Manifestations

Overdose presentations are primarily associated with the accidental or intentional oral ingestion of Phenothrin, which leads to signs of systemic neurotoxicity. Documented manifestations include headache, dizziness, nausea, vomiting, abdominal pain, and excessive salivation. Following extensive exposure, severe outcomes can include life-threatening complications such as convulsions, severe muscle fasciculations, impaired consciousness, and coma. Ingestion also carries a risk of respiratory distress and potential aspiration pneumonitis due to the solvent base present in certain formulations. Children are specifically noted in regulatory documents as a population at risk for severe complications following accidental ingestion.

Emergency Action Requirements

Immediate medical attention must be sought in all cases of suspected overdose or if severe symptoms are observed. Official regulatory guidance mandates contacting a Poison Control Center or immediate transfer to a medical facility when severe signs of poisoning are present.

Management and Monitoring

Treatment is strictly symptomatic and supportive, as regulatory documents state that no specific antidote is known. Procedural management outlined in authoritative sources includes administering intravenous diazepam for prolonged seizures. Continuous observation and monitoring, including checks for liver function and potential pulmonary edema, are required. Gastric lavage is often advised against due to the aspiration hazard posed by the product's solvent content.

Therapeutic Uses of Anti-bit

What Anti-bit Treats: Main Uses and Benefits

Symptomatic Support for Acute Discomfort

This medicine is primarily used in situations involving symptoms related to physical discomfort that may appear suddenly or intensify temporarily. The therapeutic scope is generally consistent with indications for supportive relief in clinical settings.

It is commonly used when short-term symptomatic assistance is needed. The specific therapeutic indications generally cover symptoms of heightened physiological activity, symptoms that interfere with daily functioning, and symptoms that create noticeable physiological strain. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, and may assist with maintaining functional stability.

“Applied in clinical settings that involve acute or unstable symptom patterns, Anti-bit may assist with maintaining functional stability.”

Quick Fact: Relevant for Symptoms of Systemic Imbalance

Management of Fluctuating Symptom Patterns

Anti-bit is generally applied across conditions characterized by episodic or fluctuating manifestations, particularly when symptom clusters appear suddenly or fluctuate. It helps address symptoms that interfere with daily comfort, applied in contexts where additional symptomatic support is needed and contributes to easing the overall symptom load. It supports patients during episodes of heightened discomfort by easing distress.

Eligibility and Restrictions for Use

Who Can and Cannot Use Anti-bit? (Phenothrin)

The population eligibility for Anti-bit, which contains the active ingredient Phenothrin, is defined by regulatory labels based on age, hypersensitivity, and physiological status.

Absolute Contraindication

The medicine is contraindicated and must not be used by patients with a known history of sensitivity or hypersensitivity to pyrethroid insecticides or related compounds such as pyrethrins.

Approved Age Groups and Conditional Use

Anti-bit is generally approved for use in adults and the elderly. Use is also permitted in children aged 6 months and above under standard labeled conditions. Use in infants under 6 months is restricted and is only permitted under medical supervision.

Population Group Eligibility Status
Adults & Elderly Permitted (Standard Use)
Children (≥ 6 months) Permitted (Standard Use)
Infants (< 6 months) Restricted (Medical Supervision Required)

Use Restrictions and Cautions

The official labeling mandates that the product must not be applied to skin that is broken or secondarily infected. Additionally, use in pregnant and lactating women is permitted but requires caution.

What should I know about interactions with other medicines?

Anti-bit, an antibiotic combination of amoxicillin and clavulanate, can interact with certain other medications, potentially affecting its efficacy or increasing the risk of side effects. It is essential to inform your healthcare provider of all prescription and over-the-counter drugs, vitamins, and herbal supplements you are taking.

Medication Interactions

Concomitant Medicine Potential Effect of Interaction
Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding due to enhanced anticoagulant effect. Close monitoring of International Normalized Ratio (INR) is necessary.
Allopurinol Increased risk of developing a skin rash (hypersensitivity reaction).
Probenecid Increases and prolongs the concentration of amoxicillin in the blood. Co-administration is generally not recommended.
Methotrexate May increase the concentration of methotrexate, potentially raising the risk of toxicity (increased side effects).
Oral Contraceptives May reduce the effectiveness of combined oral contraceptives (birth control pills). An alternative or additional form of contraception may be required.

Other Considerations

Although there are no specific, severe interactions between Anti-bit and alcohol, consuming alcohol may worsen common gastrointestinal side effects such as nausea and diarrhea. There are no known significant interactions with specific foods; however, taking the medication with a meal may help reduce stomach upset. Anti-bit may also interfere with certain laboratory tests for urine glucose, leading to false positive results.

Mechanism of Action

Modulating Voltage-Gated Sodium Channels

The mechanism of Anti-bit is centered on the voltage-gated sodium channels (VGSCs) within the ectoparasite's neuronal membranes. The active ingredient, Phenothrin, acts as a modulator that binds to these channels, preventing their normal closure (inactivation) after an electrical impulse. This forced, prolonged opening causes an uncontrolled and massive influx of sodium ions ( Na^+), triggering sustained, repetitive depolarization of the nerve cell.

Inducing Systemic Neurotoxicity and Paralysis

This molecular action immediately translates into the disruption of the parasite's nervous system signaling. The persistent, disorganized electrical firing overwhelms both the peripheral and central motor nervous systems, resulting in acute hyper-excitation and the complete loss of motor control. This sequence is known as the neurotoxic cascade, which culminates rapidly in systemic paralysis, resulting in the physiological consequence of parasite death.

Constraints on Mechanistic Activity

The mechanistic activity of Phenothrin is constrained by resistance mechanisms developed by some ectoparasite populations. This includes target-site resistance, where specific genetic mutations in the VGSC reduce the molecule's binding affinity, and metabolic resistance, where the parasite increases the expression of detoxifying enzymes, such as P450 monooxygenases, which rapidly degrade Phenothrin before it can successfully engage the sodium channels.

Dosage and Administration Information

How to use Anti-bit — Official Administration Guidelines

Anti-bit (Phenothrin) is administered strictly as a topical product, with official usage patterns focused on non-systemic application to the infested area.


Administration Scope

Property Value
Route of administration Topical (application to the hair and scalp/body surface).
Dosing schedule Application of a sufficient volume of the product to thoroughly saturate the hair and scalp.
Timing in relation to meals (if applicable) Not applicable; administration is topical.
Preparation requirements (if applicable) Apply the product to the hair and rinse with water after the specified contact time.
Age-group administration rules Approved for use in Adults and children 2 years of age and older.
Missed-dose rules Not applicable; the regimen is based on acute, timed applications, not daily dosing.
Special procedural conditions The product must remain on the hair for a specific, labeled duration, typically 10 minutes, before being rinsed off.

Instruction Classifications (High-level)

Property Value
Administration method type Topical application.
Frequency pattern Single initial application followed by a mandated reapplication 7 to 10 days later.
Regulatory basis Consistent with established product monographs.
Use-context constraints Must be used for external use only; contact with the eyes and mucous membranes must be avoided.

Resulting Procedural Structure

Official step sequence:

  • Step 1: Apply the product to the affected area in a saturating volume.
  • Step 2: Allow the product to remain in contact for the officially specified duration (e.g., 10 minutes).
  • Step 3: Rinse the hair thoroughly using water.
  • Step 4: Use a fine-toothed comb to remove dead ectoparasites and nits after rinsing.
  • Step 5: Perform the full procedure again 7 to 10 days after the initial treatment.

Connection to the overall use protocol (2–4 sentences):

The full use protocol is defined by the topical route and a two-part treatment cycle separated by a specific interval to address the life cycle of the parasite. The instructions establish standardized actions—contact time, rinsing, and combing—which are necessary procedural steps for the administration of the medicine. This regimented approach ensures the consistent, acute application described for this application.

Recent Clinical Evidence

Research evidence / Overview of Studies for Anti-bit

Evidence for Use in Head Louse Infestation (Pediculosis Capitis)

Phenothrin was studied for its intended purpose of eliminating lice infestations on the head, which is known as Pediculosis Capitis. The research base exploring this use is supported by Randomized Controlled Trials (RCTs) and controlled comparative studies. This research examined patterns of change in the observed populations, and whether studies observed the absence of ectoparasites over defined time intervals. The main outcomes that researchers monitored were the Eradication Rate, defined as the absence of live lice or nymphs, and the ovicidal activity endpoint, which measured egg viability.

Studies report that research has explored the application of Phenothrin to populations of children and adults with a confirmed presence of ectoparasites. Findings describe patterns observed in the studies related to measurements of louse absence in the short-term. The measured outcomes were observed in some studies to be influenced by factors such as the application technique.

Comparing Anti-bit to Other Treatments

Research has also examined Phenothrin in comparison to other methods commonly used for head lice, including alternative chemical treatments and mechanical removal techniques. In these comparative research scenarios, studies monitored the overall success rate for eliminating the infestation across all groups.

Research so far indicates that while the medicine was evaluated in trials against other products, findings were mixed. The data show patterns related to inconsistent performance in regions where lice have developed resistance to insecticides of the pyrethroid class. This evidence contributes to understanding symptom patterns, but the patterns of reported success were observed to vary depending on local resistance levels.

Understanding Inconsistent Findings and Evidence Gaps

One of the most significant research limitation frames is the presence of insecticide resistance, as reported by researchers. Research indicates that in populations where lice have developed resistance to pyrethroids, the product's effectiveness may be lower than reported in initial trials. Another key area of uncertainty is the data regarding the ovicidal activity endpoint. Research suggests that limited ovicidal activity was associated with treatment failure in some studies. Long-term effects are not fully established, as follow-up durations in the primary clinical trials were typically limited to 14 days.

Key Studies & References

  1. Head lice - Diagnosis & treatment - Mayo Clinic (Clinical Overview/Guidance addressing treatment failures and resistance)

Frequently Asked Questions (FAQ)

Common questions about Anti-bit (FAQ)


Q: How long is Anti-bit typically used for?

Official product labeling states that the treatment is generally repeated after seven days. Regulatory documents indicate that use for continued prolonged treatment beyond three consecutive weeks is not recommended.


Q: How quickly does Anti-bit usually start to have an effect?

Official information about the drug's mechanism of action (MoA) describes it as a fast-acting neurotoxin. The mechanism is designed to cause rapid paralysis in the target organism, supporting a fast onset of effect.


Q: What is the typical timeframe to see the maximum effect of Anti-bit?

The product labeling recommends a second application seven days after the first. The full treatment efficacy is generally evaluated following the recommended re-treatment period, which helps eliminate any newly hatched parasites.


Q: Do studies suggest Anti-bit loses its effect over time?

The product label recommends a repeat treatment after seven days. This re-treatment is necessary to address the parasite's life cycle and target organisms that may hatch after the initial application.


Q: Are there any known long-term side effects that official sources describe for Anti-bit?

According to official regulatory safety data, extensive animal studies have been conducted. Regulatory studies examining long-term effects have not indicated that the active ingredient causes cancer or affects reproductive health.


Q: What are the signs of a serious, but rare, side effect of Anti-bit?

Serious systemic effects are extremely rare and have been documented primarily in cases of substantial accidental ingestion, rather than typical topical use. Signs of severe poisoning include coma, convulsions, and severe muscle twitching (fasciculations).


Q: What is the official chemical name for Anti-bit?

The official chemical name for the active ingredient is (3-phenoxyphenyl)methyl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate. The ingredient is commonly known by its simpler drug name, Phenothrin.


Q: What happens if Anti-bit is taken with supplements like St. John's Wort?

Official safety information does not list an interaction with St. John's Wort. Due to the minimal systemic absorption of the topical medicine, systemic drug-supplement interactions are generally not expected to occur.


Q: Why is Anti-bit not recommended for children?

Official regulatory documents restrict its use based on age. The product is generally labeled for use in children aged six months and older, and official labeling limits its use in younger infants to under medical supervision.


Q: Is Anti-bit safe for women who are planning pregnancy?

Data on use during the pre-conception period is limited. Official caution is advised for use during this time, consistent with all medications, due to the limited data available.


Q: Can people with mild kidney issues use Anti-bit?

Official safety data indicates that the active ingredient is poorly absorbed through the skin. Normal topical use is considered unlikely to affect kidney function, given the product's poor absorption.


Q: Can people with a history of seizures take Anti-bit?

The active ingredient is classified as a neurotoxin. However, the risk of triggering seizures is primarily associated with substantial accidental ingestion or severe poisoning, rather than with the correct topical application of the medicine.


Q: What is the connection between Anti-bit and liver health?

The body relies on the liver to break down (metabolize) the active ingredient. While high-dose animal studies have suggested a potential effect on the liver, the liver is the primary organ responsible for breaking down the drug's components for elimination.


Q: Is Anti-bit available generically?

Yes, official sources confirm that the active ingredient, Phenothrin, is a generic chemical. It is widely used in multiple commercially available products across various jurisdictions.


Q: Is it normal to feel a bit restless when taking Anti-bit?

The active ingredient belongs to a class of compounds known to affect the nervous system. In some reported exposures, regulatory safety data has noted central nervous system effects such as restlessness and irritability.


Q: Can Anti-bit cause weight changes?

Official regulatory safety data for the topical use of this medicine has not documented weight changes in human patients.


Q: Are there different strengths of Anti-bit available?

The active ingredient is manufactured in various concentrations. Therefore, the specific product you use may be available in different strengths or formulations depending on the manufacturer.


Q: What is the difference between Anti-bit and its active metabolite?

When the body processes the active ingredient, it breaks it down into chemical components called metabolites. These metabolites are inactive, allowing them to be eliminated quickly from the body.


Q: How does the body break down and eliminate Anti-bit?

The body primarily breaks down the active ingredient in the liver through a process called metabolism. The resulting non-toxic compounds are then largely eliminated from the body via the urine.


Q: Is Anti-bit classified as a controlled substance?

No, official regulatory reviews confirm that the active ingredient is not classified as a controlled substance. It is not scheduled by the US Drug Enforcement Administration or equivalent international bodies.


Q: Do official documents mention the risk of dizziness with Anti-bit?

Yes, dizziness is listed as a symptom that has been reported following some types of exposure to the active ingredient.


Q: How does Anti-bit affect driving or operating machinery?

While many product labels state no known effects, product labeling or associated safety data suggests that reported symptoms, such as dizziness, could temporarily impair the ability to drive or operate complex machinery.


Q: What are the main things to avoid while taking Anti-bit?

Official warnings caution that the product must not come into contact with the eyes or broken/infected skin. Due to components in the formulation, contact with naked flames or high heat sources must also be avoided until the product is completely dry.


Q: Can people with asthma use the Anti-bit lotion?

Regulatory warnings note that the alcohol content in some liquid formulations has been associated with wheezing in susceptible patients, such as those with asthma. It may also cause inflammation in individuals who have severe eczema.

How should Anti-bit be stored and disposed of?

How to Store and Dispose of Anti-bit

The storage and disposal of Anti-bit (Phenothrin topical) must strictly follow official regulatory requirements to maintain product stability and ensure household safety.


Official Storage Conditions

Anti-bit must be stored at Controlled Room Temperature, maintained between 20 C to 25 C. The product must be protected from light and moisture and should not be exposed to excessive heat. To maintain integrity, the medicine must be kept in its original container and the container must remain tightly closed.

Storage Requirement Specification
Temperature 20 C to 25 C (68 F to 77 F)
Protection Protect from light and moisture
Container Store in original, tightly closed container

Disposal and Child Safety

It is mandatory to keep Anti-bit out of the sight and reach of children. Unused or expired Anti-bit must be disposed of according to local regulations for medicinal waste. Due to its ectoparasiticide classification, the product must not be poured down the sink or disposed of in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anti-bit found in:

A-Z Index: